Seres Therapeutics SER-109 Phase 2 Microbiome 2017

Presentation of Phase 2 clinical trial data for SER-109, a microbiome therapeutic candidate for Clostridioides difficile infection recurrence. The deck details dysbiosis mechanisms, antibiotic-mediated pathophysiology, and the therapeutic potential of microbiome restoration to restore bacterial diversity and reduce C. difficile recurrence risk.